Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.

Biochemical and biophysical research communications - 18 Sept 2018

Ma Rui, Yun Cai-Hong

Abstract excerpt

Some mutations of isocitrate dehydrogenase 1 and 2 observed in multiple kinds of malignant tumors can lead to a neomorphic enzyme activity that converts alpha-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG). As an oncometabolite, 2-HG can cause epigenetic changes and impair cell differentiation. Inhibiting the activity of isocitrate dehydrogenase mutants (mIDH) is considered to be an effective therapy for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Site
Share to Crystallography, X-Ray
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Isocitrate Dehydrogenase

Share to Mutant Proteins

Share to Neoplasms

Share to Protein Conformation

Source

Identifiers

PMID: 30131249
DOI: 10.1016/j.bbrc.2018.08.068

Genes

IDH1
IDH2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.PMID 30131249Read ↗

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.Semantic proximity Read ↗

Recent advances of IDH1 mutant inhibitor in cancer therapySemantic proximity Read ↗

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.Semantic proximity Read ↗

Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach.Semantic proximity Read ↗

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assaysSemantic proximity Read ↗

The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.Semantic proximity Read ↗

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular DifferentiationSemantic proximity Read ↗

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancerSemantic proximity Read ↗

Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Semantic proximity Read ↗

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers.Semantic proximity Read ↗

Active site remodeling in tumor-relevant IDH1 mutants drives distinct kinetic features and potential resistance mechanismsSemantic proximity Read ↗

Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.